Clinical Medical Policy Department Clinical Affairs Division DESCRIPTION
|
|
- Britton Boone
- 6 years ago
- Views:
Transcription
1 Prothrombin Time/International Normalized Ratio (PT/INR) Monitor for Home Anticoagulation Management [For the list of services and procedures that need preauthorization, please refer to Go to Comunicados a Proveedores, and click Cartas Circulares.] Medical Policy: MP-ME Original Effective Date: November 20, 2008 Revised : October 31, 2017 Next Revision: October, 2018 This policy applies to products subscribed by the following corporations, MCS Life Insurance Company (Commercial), and MCS Advantage, Inc. (Classicare) and, provider s contract; unless specific contract limitations, exclusions or exceptions apply. Please refer to the member s benefit certification language for benefit availability. Managed care guidelines related to referral authorization, and precertification of inpatient hospitalization, home health, home infusion and hospice services apply subject to the aforementioned exceptions. DESCRIPTION Anticoagulant therapy drugs - (Warfarin) Is a prescription drug that interferes with normal blood clotting (coagulation), it is also called an anticoagulant. Many people refer to these drugs as "blood thinners," although they do not actually cause the blood to become less thick, only less likely to clot. The normal clotting mechanism is a complex process that involves multiple substances (clotting factors). These factors are produced by the liver and act in sequence to form a blood clot. In order for the liver to produce some of the clotting factors, adequate amounts of vitamin K must be available. Warfarin blocks one of the enzymes that uses vitamin K to make some of the clotting factors, and in turn reduces their production. As a result, the clotting mechanism is disrupted and it takes longer for the blood to clot. The goal of warfarin therapy is to decrease the clotting tendency of blood, but not to prevent clotting completely. Therefore, the blood's ability to clot must be carefully monitored while a person takes warfarin. The dose of warfarin is adjusted to maintain the clotting time within a target range, based on the results of periodic blood tests. These tests can be done in a laboratory or using a portable device at home. According to the scientific literature, Prothrombin time (PT) is the most frequently used method of monitoring the therapeutic effectiveness of Warfarin. PT is a test that measures the amount of time it takes for a person s blood to clot. They describe at least 3 methods of monitoring anticoagulation: Physician s office usually once a month. Anticoagulation clinics usually once every 2-3 weeks. Home prothrombin time monitors. A PT/INR Home Monitoring System is a portable testing device that includes a finger-stick and an FDAcleared meter that measures the time it takes for a person s blood plasma to clot. The approach of the 1
2 PT/INR home monitoring system is similar to home blood glucose monitoring for diabetics. Patient selftesting and self-management with the use of a home INR monitor may be used to improve the time in therapeutic rate (TTR) for select groups of patients. Increased TTR leads to improved clinical outcomes and reductions in thromboembolic and hemorrhagic events. COVERAGE Benefits may vary between groups and contracts. Please refer to the appropriate member certificate and subscriber agreement contract for applicable diagnostic imaging, DME, laboratory, machine tests, benefits and coverage. INDICATIONS I., (MCS) will consider medically necessary the use of Home Prothrombin Time Testing to monitor chronic oral anticoagulation for members on Warfarin: 1. With mechanical heart valves; or 2. Chronic atrial fibrillation; or 3. Venous thromboembolism (inclusive of deep venous thrombosis and pulmonary embolism). II. The Monitor and the Home testing must be prescribed by a treating physician and ALL the following requirements must be met: 1. The patient must have been anticoagulated for at least 3 months prior to use of the home INR device and require long term anticoagulation (1 year or longer). 2. The patient must require weekly determinations of PT/INR values to ensure that the patient s PT/INR is in the therapeutic range. 3. The patient or caregiver must undergo a face to face educational program on anticoagulation management and must have demonstrated the correct use of the device prior to its use in the home. 4. The patient continues to correctly use the device in the context of the management of the anticoagulation therapy following the initiation of home monitoring. 5. Self-testing with the device should not occur more frequently than once a week. CONTRAINDICATIONS / LIMITATIONS 1. Porcine valves are not included in this policy, therefore MCS will not make payment on Home INR Monitoring for patients with porcine valves. 2
3 CODING INFORMATION HCPCS CODES (List may not be all inclusive) HCPCS CODES DESCRIPTION G0248 G0249 G0250 Demonstration, prior to initiation, of home INR monitoring for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria, under the direction of a physician; includes: faceto-face demonstration of use and care of the INR monitor, obtaining at least one blood sample, provision of instructions for reporting home INR test results, and documentation of patient s ability to perform testing and report. Provision of test materials and equipment for home INR monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria; includes provision of materials for use in the home and reporting of test results to physician; testing not occurring more frequently than once a week; testing materials, billing units of service include 4 tests. Physician review, interpretation, and patient management of home INR testing for a patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria; testing not occurring more frequently than once a week; billing units of service include 4 tests HCPCS LEVEL II Professional Edition (American Medical Association). ICD-10 Codes (List may not be all inclusive) ICD-10-Codes DESCRIPTION D68.51 Activated protein C resistance D68.52 Prothrombin gene mutation D68.59 Other primary thrombophilia D68.61 Antiphospholipid syndrome D68.62 Lupus anticoagulant syndrome I26.01 Septic pulmonary embolism with acute cor pulmonale I23.6 Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction I26.09 Other pulmonary embolism with acute cor pulmonale I26.90 Septic pulmonary embolism without acute cor pulmonale I26.99 Other pulmonary embolism without acute cor pulmonale I27.82 Chronic pulmonary embolism I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.91 Unspecified atrial fibrillation I67.6 Nonpyogenic thrombosis of intracranial venous system I80.00 Phlebitis and thrombophlebitis of superficial vessels of unspecified lower 3
4 I80.01 Phlebitis and thrombophlebitis of superficial vessels of right lower I80.02 Phlebitis and thrombophlebitis of superficial vessels of left lower I80.03 Phlebitis and thrombophlebitis of superficial vessels of lower extremities, I80.10 Phlebitis and thrombophlebitis of unspecified femoral vein I80.11 Phlebitis and thrombophlebitis of right femoral vein I80.12 Phlebitis and thrombophlebitis of left femoral vein I80.13 Phlebitis and thrombophlebitis of femoral vein, I Phlebitis and thrombophlebitis of unspecified deep vessels of right lower I Phlebitis and thrombophlebitis of unspecified deep vessels of left lower I Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities, I Phlebitis and thrombophlebitis of unspecified deep vessels of unspecified lower I Phlebitis and thrombophlebitis of right iliac vein I Phlebitis and thrombophlebitis of left iliac vein I Phlebitis and thrombophlebitis of iliac vein, I Phlebitis and thrombophlebitis of unspecified iliac vein I Phlebitis and thrombophlebitis of right popliteal vein I Phlebitis and thrombophlebitis of left popliteal vein I Phlebitis and thrombophlebitis of popliteal vein, I Phlebitis and thrombophlebitis of unspecified popliteal vein I Phlebitis and thrombophlebitis of right tibial vein I Phlebitis and thrombophlebitis of left tibial vein I Phlebitis and thrombophlebitis of tibial vein, I Phlebitis and thrombophlebitis of unspecified tibial vein I Phlebitis and thrombophlebitis of other deep vessels of right lower I Phlebitis and thrombophlebitis of other deep vessels of left lower I Phlebitis and thrombophlebitis of other deep vessels of lower, I Phlebitis and thrombophlebitis of other deep vessels of unspecified lower I80.3 Phlebitis and thrombophlebitis of lower extremities, unspecified I80.8 Phlebitis and thrombophlebitis of other sites I80.9 Phlebitis and thrombophlebitis of unspecified site I82.0 Budd-Chiari syndrome I82.1 Thrombophlebitis migrans I Acute embolism and thrombosis of superior vena cava I Chronic embolism and thrombosis of superior vena cava I Acute embolism and thrombosis of inferior vena cava I Chronic embolism and thrombosis of inferior vena cava 4
5 I Acute embolism and thrombosis of other thoracic veins I Chronic embolism and thrombosis of other thoracic veins I82.3 Embolism and thrombosis of renal vein I Acute embolism and thrombosis of unspecified deep veins of right lower I Acute embolism and thrombosis of unspecified deep veins of left lower I Acute embolism and thrombosis of unspecified deep veins of lower, I Acute embolism and thrombosis of unspecified deep veins of unspecified lower I Acute embolism and thrombosis of right femoral vein I Acute embolism and thrombosis of left femoral vein I Acute embolism and thrombosis of femoral vein, I Acute embolism and thrombosis of unspecified femoral vein I Acute embolism and thrombosis of right iliac vein I Acute embolism and thrombosis of left iliac vein I Acute embolism and thrombosis of iliac vein, I Acute embolism and thrombosis of unspecified iliac vein I Acute embolism and thrombosis of right popliteal vein I Acute embolism and thrombosis of left popliteal vein I Acute embolism and thrombosis of popliteal vein, I Acute embolism and thrombosis of unspecified popliteal vein I Acute embolism and thrombosis of right tibial vein I Acute embolism and thrombosis of left tibial vein I Acute embolism and thrombosis of tibial vein, I Acute embolism and thrombosis of unspecified tibial vein I Acute embolism and thrombosis of other specified deep vein of right lower I Acute embolism and thrombosis of other specified deep vein of left lower I Acute embolism and thrombosis of other specified deep vein of lower, I Acute embolism and thrombosis of other specified deep vein of unspecified lower I82.4Y1 Acute embolism and thrombosis of unspecified deep veins of right proximal lower I82.4Y2 Acute embolism and thrombosis of unspecified deep veins of left proximal lower I82.4Y3 Acute embolism and thrombosis of unspecified deep veins of proximal lower, I82.4Y9 Acute embolism and thrombosis of unspecified deep veins of unspecified proximal lower 5
6 I82.4Z1 Acute embolism and thrombosis of unspecified deep veins of right distal lower I82.4Z2 Acute embolism and thrombosis of unspecified deep veins of left distal lower I82.4Z3 Acute embolism and thrombosis of unspecified deep veins of distal lower, I82.4Z9 Acute embolism and thrombosis of unspecified deep veins of unspecified distal lower I Chronic embolism and thrombosis of unspecified deep veins of right lower I Chronic embolism and thrombosis of unspecified deep veins of left lower I Chronic embolism and thrombosis of unspecified deep veins of lower, I Chronic embolism and thrombosis of unspecified deep veins of unspecified lower I Chronic embolism and thrombosis of right femoral vein I Chronic embolism and thrombosis of left femoral vein I Chronic embolism and thrombosis of femoral vein, I Chronic embolism and thrombosis of unspecified femoral vein I Chronic embolism and thrombosis of right iliac vein I Chronic embolism and thrombosis of left iliac vein I Chronic embolism and thrombosis of iliac vein, I Chronic embolism and thrombosis of unspecified iliac vein I Chronic embolism and thrombosis of right popliteal vein I Chronic embolism and thrombosis of left popliteal vein I Chronic embolism and thrombosis of popliteal vein, I Chronic embolism and thrombosis of unspecified popliteal vein I Chronic embolism and thrombosis of right tibial vein I Chronic embolism and thrombosis of left tibial vein I Chronic embolism and thrombosis of tibial vein, I Chronic embolism and thrombosis of unspecified tibial vein I Chronic embolism and thrombosis of other specified deep vein of right lower I Chronic embolism and thrombosis of other specified deep vein of left lower I Chronic embolism and thrombosis of other specified deep vein of lower, I Chronic embolism and thrombosis of other specified deep vein of unspecified lower I82.5Y1 Chronic embolism and thrombosis of unspecified deep veins of right proximal lower 6
7 I82.5Y2 Chronic embolism and thrombosis of unspecified deep veins of left proximal lower I82.5Y3 Chronic embolism and thrombosis of unspecified deep veins of proximal lower, I82.5Y9 Chronic embolism and thrombosis of unspecified deep veins of unspecified proximal lower I82.5Z1 Chronic embolism and thrombosis of unspecified deep veins of right distal lower I82.5Z2 Chronic embolism and thrombosis of unspecified deep veins of left distal lower I82.5Z3 Chronic embolism and thrombosis of unspecified deep veins of distal lower, I82.5Z9 Chronic embolism and thrombosis of unspecified deep veins of unspecified distal lower I Acute embolism and thrombosis of unspecified veins of right upper I Acute embolism and thrombosis of unspecified veins of left upper I Acute embolism and thrombosis of unspecified veins of upper, I Acute embolism and thrombosis of unspecified veins of unspecified upper I Acute embolism and thrombosis of superficial veins of right upper I Acute embolism and thrombosis of superficial veins of left upper I Acute embolism and thrombosis of superficial veins of upper, I Acute embolism and thrombosis of superficial veins of unspecified upper I Acute embolism and thrombosis of deep veins of right upper I Acute embolism and thrombosis of deep veins of left upper I Acute embolism and thrombosis of deep veins of upper, I Acute embolism and thrombosis of deep veins of unspecified upper I Chronic embolism and thrombosis of unspecified veins of right upper I Chronic embolism and thrombosis of unspecified veins of left upper I Chronic embolism and thrombosis of unspecified veins of upper, I Chronic embolism and thrombosis of unspecified veins of unspecified upper I Chronic embolism and thrombosis of superficial veins of right upper I Chronic embolism and thrombosis of superficial veins of left upper I Chronic embolism and thrombosis of superficial veins of upper, I Chronic embolism and thrombosis of superficial veins of unspecified upper I Chronic embolism and thrombosis of deep veins of right upper I Chronic embolism and thrombosis of deep veins of left upper 7
8 I Chronic embolism and thrombosis of deep veins of upper, I Chronic embolism and thrombosis of deep veins of unspecified upper I Embolism and thrombosis of superficial veins of right lower extremities I Embolism and thrombosis of superficial veins of left lower extremities I Embolism and thrombosis of superficial veins of lower extremities, I Embolism and thrombosis of superficial veins of unspecified lower extremities I Acute embolism and thrombosis of other specified veins I Chronic embolism and thrombosis of other specified veins I82.90 Acute embolism and thrombosis of unspecified vein I82.91 Chronic embolism and thrombosis of unspecified vein I82.A11 I82.A12 I82.A13 I82.A19 I82.A21 I82.A22 I82.A23 I82.A29 I82.B11 I82.B12 I82.B13 I82.B19 I82.B21 I82.B22 I82.B23 I82.B29 I82.C11 I82.C12 I82.C13 I82.C19 I82.C21 I82.C22 I82.C23 I82.C29 Acute embolism and thrombosis of right axillary vein Acute embolism and thrombosis of left axillary vein Acute embolism and thrombosis of axillary vein, Acute embolism and thrombosis of unspecified axillary vein Chronic embolism and thrombosis of right axillary vein Chronic embolism and thrombosis of left axillary vein Chronic embolism and thrombosis of axillary vein, Chronic embolism and thrombosis of unspecified axillary vein Acute embolism and thrombosis of right subclavian vein Acute embolism and thrombosis of left subclavian vein Acute embolism and thrombosis of subclavian vein, Acute embolism and thrombosis of unspecified subclavian vein Chronic embolism and thrombosis of right subclavian vein Chronic embolism and thrombosis of left subclavian vein Chronic embolism and thrombosis of subclavian vein, Chronic embolism and thrombosis of unspecified subclavian vein Acute embolism and thrombosis of right internal jugular vein Acute embolism and thrombosis of left internal jugular vein Acute embolism and thrombosis of internal jugular vein, Acute embolism and thrombosis of unspecified internal jugular vein Chronic embolism and thrombosis of right internal jugular vein Chronic embolism and thrombosis of left internal jugular vein Chronic embolism and thrombosis of internal jugular vein, Chronic embolism and thrombosis of unspecified internal jugular vein O22.50 Cerebral venous thrombosis in pregnancy, unspecified trimester O22.51 Cerebral venous thrombosis in pregnancy, first trimester O22.52 Cerebral venous thrombosis in pregnancy, second trimester 8
9 O22.53 Cerebral venous thrombosis in pregnancy, third trimester O87.3 Cerebral venous thrombosis in the puerperium T80.0XXA T81.718A T81.72XA T82.817A T82.818A Air embolism following infusion, transfusion and therapeutic injection, initial encounter Complication of other artery following a procedure, not elsewhere classified, initial encounter Complication of vein following a procedure, not elsewhere classified, initial encounter Embolism of cardiac prosthetic devices, implants and grafts, initial encounter Embolism of vascular prosthetic devices, implants and grafts, initial encounter Z79.01 Long term (current) use of anticoagulants Z Personal history of other venous thrombosis and embolism Z95.2 Presence of prosthetic heart valve Z95.4 Presence of other heart-valve replacement REFERENCES 1. Bereznicki, L.R., Jackson, S.L., Peterson, G.M., Jeffrey, E.C., Marsden, K.A., Jupe, D.M. (2007, March). Accuracy and clinical utility of the CoaguChek XS portable international normalised ratio monitor in a pilot study of warfarin home-monitoring. J. Clin. Pathol., 60(3), Epub 2006, Jun 2. DOI: /jcp Accessed September 18, Available at URL address: 2. Centers for Medicare & Medicaid Services. CMS Manual System. Medicare Claims Processing Manual, PUB Transmittal Change Request Date January 8, Effective Date: March 19, Implementation Date: February 9, Accessed September 18, Available at URL address: Guidance/Guidance/Transmittals/downloads/r1663cp.pdf 3. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation Management (190.11). Effective Date of this Version: 3/19/2008. Accessed September 18, Available at URL address: 4. Centers for Medicare & Medicaid Services. Medicare National Coverage Determinations Manual, Ch. 1, Part 3 (Section ) Coverage Determinations. Rev. 181, 3/27/2015. Accessed September 18, Available at URL address: Guidance/Guidance/Manuals/Downloads/ncd103c1_Part3.pdf 5. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. Chapter 32 Billing Requirements for Special Services. Rev. 3848, Section 60 - Coverage and Billing for Home Prothrombin Time (PT/INR) Monitoring for Home Anticoagulation Management. 9
10 Accessed October 26, Available at URL address: Guidance/Guidance/Manuals/downloads/clm104c32.pdf 6. Keeling. D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen, S., et al. (2011, August). Guidelines on oral anticoagulation with warfarin - fourth edition. Br. J. Haematol., 154(3), doi: /j x. Epub 2011 Jun 14. Accessed September 18, Available at URL: 7. NICE.org. Anticoagulation Therapy commissioning guide. Dated: May 13, NICE commissioning guides [CMG49]. Accessed September 18, Available at URL Address: and at URL address: oagulation.pdf 8. Perry, D.J., Fitzmaurice, D.A., Kitchen, S., Mackie, I.J. & Mallett, S. (2010). Point-of-care testing in hemostasis. Br. J. Haematol., 150, Accessed September 18, Available at URL: 9. Ryan, F., Byrne, S. & O Shea, S. (2009). Randomized controlled trial of supervised patient selftesting of warfarin therapy using an internet-based expert system. Journal of Thrombosis and Haemostasis, 7, DOI: /j x. Accessed September 18, Available at URL: UpToDate / Hull, R.D., & Garcia, D.A. (2017) Patient information: Warfarin (Coumadin) (Beyond the Basics). Literature review current through: Sep This topic last updated: Aug 18, Accessed September 18, Available at URL Address: Roche Diagnostics. (2016). CoaguChek - Oral Anticoagulation Therapies. Accessed September 18, Available at URL: ation_therapy.html POLICY HISTORY DATE ACTION COMMENT November 6, 2008 Origination of Policy January 21, 2010 Revised Policy revised to add fragment under indications with Mechanical Heart valves, chronic atrial fibrillation, or venous thromboembolism (inclusive of deep venous thrombosis and pulmonary embolism). References updated, ICD-9 added. January 21, 2011 Yearly Review Limitation added: Porcine valves are not included in this policy; & MCS will not make payment on Home INR Monitoring for patients with porcine valves. March 16, 2012 Yearly Review References updated. May 28, 2013 Revised References updated. New reference added: numbers 3 & 5. To Coding Information Added: New ICD-9 Codes ,
11 August 1, 2013 Reviewed References updated. September 16, 2013 Reviewed References updated. February 21,2014 Revised To the Coding section: A new ICD-10 Codes (Preview Draft) section was added to the policy. May 21, 2014 Revised References updated. Description section was restructured with new information. To the References Section: References (#6, 7, 8, and 9) were added to the Policy. August 14, 2015 Revised References updated. To the Description Section: Information in the First Paragraph was adapted to this new description to read as: Anticoagulant therapy drugs (Warfarin) is a kind of oral anticoagulant prescription drug that is prescribed to prevent harmful blood clots from forming or growing larger. Beneficial blood clots prevent or stop bleeding, but harmful blood clots can cause a heart attack, stroke, deep vein thrombosis or pulmonary embolism. Because warfarin interferes with the formation of blood clots, it is called an anticoagulant. The effect of Warfarin on the bloods ability to clot must be carefully monitored in order to prescribe the appropriate dosage adjustment for patients on this drug. Fifth Paragraph was reviewed and restructured in a new manner according to this new document: NICE.org. 3 Monitoring the safety and quality of anticoagulation therapy. Dated: May NICE commissioning guides [CMG49] to read as: Prothrombin time (PT) is the most frequently used method of monitoring the therapeutic effectiveness of Warfarin. PT is a test that measures the amount of time it takes for a person s blood to clot. There are at least 3 clinical settings where monitoring anticoagulation can take place: Hospital outpatient Primary care; and Community settings To the References Section: New Reference #8 was added to the Policy. November 23, 2015 Revised To the coding section: Eliminate ICD-9 codes since they are no longer valid for diagnosis classification. Add new section of ICD-10 codes which are the valid diagnosis classification system since October 1, June 23, 2015 Revised To the Description Section: Information was restructured. Some paragraphs were fixed. To the Coding Section: To the ICD-10 Codes Section: New ICD-10 Codes were added to the Policy: I23.6, I26.09, I27.82, I67.6, I82.211, I82.291, I82.501, I82.502, I82.503, I82.509, I82.511, I82.512, I82.513, I82.519, I82.521, I82.522, I82.523, I82.529, I82.531, I82.532, I82.533, I82.539, I82.541, I82.542, I82.543, I82.549, I82.591, I82.592, I82.593, I82.599, I82.5Y1, I82.5Y2, I82.5Y3, I82.5Y9, I82.5Z1, I82.5Z2, I82.5Z3, I82.5Z9, I82.701, I82.702, I82.703, I82.709, I82.711, 11
12 I82.712, I82.713, I82.719, I82.721, I82.722, I82.723, I82.729, I82.811, I82.812, I82.813, I82.819, I82.891, I82.A21, I82.A22, I82.A23, I82.A29, I82.B21, I82.B22, I82.B23, I82.B29, I82.C21, I82.C22, I82.C23, I82.C29, O22.50, O22.51, O22.52, O22.53, O87.3 and Z To the References Section: New Reference #10 was added to the Policy. October 31, 2017 Revised References updated. To the Description Section: To 4 th paragraph: Modified 3 rd sentence which now reads: They describe at least 3 methods of monitoring anticoagulation. To the Coding Section: Added new ICD-10-CM codes: Z & Z95.4 This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member s plan in effect as of the date services are rendered., (MCS) medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Medical Card System, Inc., (MCS) reserves the right to review and update its medical policies at its discretion. ; (MCS) medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan s ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide. 12
Clinical Policy Title: Prothrombin international normalized ratio self-testing
Clinical Policy Title: Prothrombin international normalized ratio self-testing Clinical Policy Number: 05.01.02 Effective Date: July 1, 2013 Initial Review Date: April 23, 2013 Most Recent Review Date:
More informationClinical Policy Title: Prothrombin international normalized ratio self-testing
Clinical Policy Title: Prothrombin international normalized ratio self-testing Clinical Policy Number: 05.01.02 Effective Date: July 1, 2013 Initial Review Date: April 23, 2013 Most Recent Review Date:
More informationEndovenous Radiofrequency and Laser Ablation
Endovenous Radiofrequency and Laser Ablation [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr go to Comunicados a Proveedores, and click Cartas Circulares.]
More informationClinical Medical Policy Department Clinical Affairs Division DESCRIPTION
Ambulatory Blood Pressure Monitoring (ABPM) [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr. go to Comunicados a Proveedores, and click Cartas Circulares.]
More informationDirect Current Therapy for Treatment of Hemorrhoids
Direct Current Therapy for Treatment of Hemorrhoids [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr go to Comunicados a Proveedores, and click Cartas
More informationA guide to anticoagulation management and self-testing
A guide to management and self-testing Understanding If you re reading this, you, or someone you care about, may be on oral therapy, usually treated with a vitamin K antagonist (VKA). VKAs, such as warfarin,
More informationMEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME MONITORING DEVICE. POLICY NUMBER: CATEGORY: Equipment/Supplies
MEDICAL POLICY SUBJECT: HOME PROTHROMBIN TIME 06/23/16, 6/22/17 PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationCardiac Disease Screening Lipid Profile
Cardiac Disease Screening Lipid Profile Date of Origin: 04/2003 Last Review Date: 08/23/2017 Effective Date: 08/23/2017 Dates Reviewed: 01/2004, 04/2005, 12/2005, 06/2006, 06/2007, 07/2008, 6/2011, 05/2012,
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Non-Invasive Peripheral Venous Studies (L35451) MP-067-MC-PA Medical Management Provider Notice Date: 05/01/2018 Issue Date:
More informationIcd 10 code for deep venous
Icd 10 code for deep venous thrombosis prophylaxis The Borg System is 100 % Icd 10 code for deep venous thrombosis prophylaxis PE. Pulmonary Embolus. F-10a Factor 10a Inhibitors. PH. Pulmonary. Hypertension.
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: CP.PHAR.225
Clinical Policy: (Fragmin) Reference Number: CP.PHAR.225 Effective Date: 05/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationClinical Audit of Warfarin Clinic the 4 th Practice Mallow Primary Healthcare Centre,
Clinical Audit of Warfarin Clinic the 4 th Practice Mallow Primary Healthcare Centre, 2011-2012 Stephanie Cronin, Elaine Mulcahy, Dr David Molony, Curtis Irvine Introduction Methods Conclusion Warfarin
More informationContractor Information. LCD Information. Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Document Information
Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
More informationMEDICAL POLICY No R9 DETOXIFICATION I. POLICY/CRITERIA
DETOXIFICATION MEDICAL POLICY Effective Date: January 1, 2018 Review Dates: 1/93, 2/97, 4/99, 2/01, 12/01, 2/02, 2/03, 1/04, 1/05, 12/05, 12/06, 12/07, 12/08, 12/09, 12/10, 12/11, 12/12, 12/13, 11/14,
More informationMedical Review Guidelines Magnetic Resonance Angiography
Medical Review Guidelines Magnetic Resonance Angiography Medical Guideline Number: MRG2001-05 Effective Date: 2/13/01 Revised Date: 2/14/2006 OHCA Reference OAC 317:30-5-24. Radiology. (f) Magnetic Resonance
More informationDiagnostics Assessment Programme. Final scope
Diagnostics Assessment Programme Self-monitoring coagulometers (CoaguChek XS system, INRatio2 PT/INR monitor and ProTime Microcoagulation system), for selftesting or self-managing coagulation status in
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Homocysteine Testing Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Homocysteine Testing Professional Institutional Original Effective Date: March
More information2016 Physician Quality Reporting System Data Collection Form: Total Knee Replacement
2016 Physician Quality Reporting System Data Collection Form: Total Knee Replacement IMPORTANT: Any measure with a 0% performance rate (100% for inverse measures) is not considered satisfactory reporting.
More informationMEDICAL POLICY SUBJECT: SURGICAL STOCKINGS AND COMPRESSION GARMENTS. POLICY NUMBER: CATEGORY: Equipment/ Supplies
MEDICAL POLICY SUBJECT: SURGICAL STOCKINGS AND PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information2018 HEMODIALYSIS CATHETERS CODING AND REIMBURSEMENT GUIDE
2018 HEMODIALYSIS CATHETERS CODING AND REIMBURSEMENT GUIDE Contents Overview of Central Venous Access s for Hemodialysis 2 Procedures Using Hemodialysis s 2 Physician Reimbursement for Hemodialysis s 3
More informationINDIANA HEALTH COVERAGE PROGRAMS
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER CODE TABLES Note: Due to possible changes in Indiana Health Coverage Programs (IHCP) policy or national coding updates, inclusion of a code on the code tables
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Anticoagulant Injectable (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationDiagnostic and interventional venous procedures (lower extremity)
Coding and Medicare national payment guide 2018 Diagnostic and interventional venous procedures (lower extremity) All coding, coverage, billing and payment information provided herein by Philips is gathered
More informationMEDICAL POLICY SUBJECT: SURGICAL STOCKINGS AND COMPRESSION GARMENTS. POLICY NUMBER: CATEGORY: Equipment/ Supplies
MEDICAL POLICY SUBJECT: SURGICAL STOCKINGS AND PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationPremier Health Plan considers Intravascular Ultrasound (IVUS) for Coronary Vessels medically necessary for the following indications:
Premier Health Plan POLICY AND PROCEDURE MANUAL MP.091.PH - Intravascular Ultrasound for Coronary Vessels This policy applies to the following lines of business: Premier Commercial Premier Employee Premier
More informationMEDICAL POLICY SUBJECT: SURGICAL STOCKINGS AND COMPRESSION GARMENTS. POLICY NUMBER: CATEGORY: Equipment/ Supplies
MEDICAL POLICY SUBJECT: SURGICAL STOCKINGS AND PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More information2018 Diagnosis Coding Fact Sheet
The information contained in this document is provided for informational purposes only and represents no statement, promise, or guarantee by Cordis Corporation concerning levels of reimbursement, payment,
More informationExcessive anticoagulation identified by emergency medical service through point-of-care coagulometry
Excessive anticoagulation identified by emergency medical service through point-of-care coagulometry BY CHRISTOPHER BEYNON, ANGELINA G ERK, STEFAN MOHR, FELIX HEISER, ERIK POPP Abstract Bleeding because
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationEvaluation of the Precision and Accuracy of the INRatio 2 Prothrombin Time (PT) Monitoring System
Evaluation of the Precision and Accuracy of the INRatio 2 Prothrombin Time (PT) Monitoring System Grace DeSantis, PhD Lisa Croner, PhD Michealle Havenhill, BA Shari Kipp, BSc (Honours) MBA Inverness Medical,
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:
More informationPartial Thromboplastin Time (PTT)
190.16 - Partial Thromboplastin Time (PTT) Other Names/Abbreviations PTT Basic plasma coagulation function is readily assessed with a few simple laboratory tests: The Partial Thromboplastin Time (PTT),
More informationMEDICAL POLICY No R1 MEDICAL MANAGEMENT OF OBESITY
MEDICAL MANAGEMENT OF OBESITY Effective Date: May 10, 2017 Review Dates: 8/11, 12/11, 2/12, 2/13, 2/14, 2/15, 2/16, 2/17 Date Of Origin: August 10, 2011 Status: Current Note: This medical policy does not
More informationCosting statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS)
Putting NICE guidance into practice Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS) Published: September
More informationCMS Limitations Guide - Radiology Services
CMS Limitations Guide - Radiology Services Starting October 1, 2015, CMS will update their existing medical necessity limitations on tests and procedures to correspond to ICD-10 codes. This limitations
More informationMedStar Health, Inc. POLICY AND PROCEDURE MANUAL Policy Number: MP.015.MH Last Review Date: 11/08/2018 Effective Date: 02/01/2019
MedStar Health, Inc. POLICY AND PROCEDURE MANUAL This policy applies to the following lines of business: MedStar Employee (Select) MedStar CareFirst PPO MedStar Health considers Compression Garments and
More informationCombined oral contraceptives and risk of venous thromboembolism: nested case control studies using the QResearch and the CPRD databases
Combined oral contraceptives and risk of venous thromboembolism: nested case control studies using the QResearch and the CPRD databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Web appendix:
More informationClinical Medical Policy Department Clinical Affairs Division DESCRIPTION
Total Parenteral Nutrition (TPN) [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr go to Comunicados a Proveedores, and click Cartas Circulares.] Medical
More informationPharmacogenomic Testing for Warfarin Response (NCD 90.1)
Policy Number 90.1 Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare
More informationI know my value. Be an active part of your anticoagulation therapy with INR self-monitoring
I know my value Be an active part of your anticoagulation therapy with INR self-monitoring INR* self-monitoring needs only a drop of blood, is easy, fast and decreases the possibility Be involved in your
More informationHomocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease Corporate Medical Policy
Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease Corporate Medical Policy File name: Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular
More informationc) What is the name of RBC (erythrocyte) formation? Where do blood cells form?
UNIT 6: CARDIOVASCULAR SYSTEM 1) List the three general functions of BLOOD. REVIEW QUESTIONS Blood 2) a) What are the three formed elements /cellular elements in blood? b) Describe the composition of the
More informationSupplemental Digital Content: Definitions Based on the International Classification of Diseases, Ninth Revision, Clinical Modification
Supplemental Digital Content: Definitions Based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnose and Procedures Codes 1. ICD-9-CM definition of
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationTRACE A DROP OF BLOOD FROM RIGHT EAR TO LEFT OCULOMOTOR NERVE
TRACE A DROP OF BLOOD FROM RIGHT EAR TO LEFT OCULOMOTOR NERVE KEY: TRACE A DROP OF BLOOD FROM RIGHT EAR TO LEFT OCULOMOTOR NERVE RIGHT EAR RIGHT ATRIUM LEFT SUBCLAVIAN ARTERY RIGHT EXTERNAL JUGULAR VEIN
More informationPartial Thromboplastin Time (PTT)
190.16 - Partial Thromboplastin Time (PTT) Other Names/Abbreviations PTT Basic plasma coagulation function is readily assessed with a few simple laboratory tests: The Partial Thromboplastin Time (PTT),
More informationPopulations Interventions Comparators Outcomes Individuals: With diagnosed heart disease. rehabilitation
Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 01/01/17 Next Review Date: 05/18 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2016 Section: Prescription Drugs
More informationENROLLMENT : Line of Business Summary
ENROLLMENT : Line of Business Summary Date Range : JAN 2017 through DEC 2017 COMPREHENSIVE MAJOR MEDICAL Print Date : 1/19/2018 9:43:49AM Page 1 of 1 Month Year Single 2 Person : Emp/Spouse 2 Person :
More informationIschemia of lower extremity icd 10
Ischemia of lower extremity icd 10 ICD-10-CM Code(s). ICD-9-CM. Diabetic chronic TEENney disease (E08.22, E09. 22, E10.22, E11.22, E13.22). Hypertensive. I83.001 Varicose veins of unspecified lower extremity
More informationUpdates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis. By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan
Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan Objectives Describe the prevalence of PE and DVT as it relates
More informationListen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need
Listen to Your Heart The S-ICD System What Everyone Needs To Know About Atrial Fibrillation & Stroke The protection you need without Stroke. touching Are you your at heart risk? Increase your knowledge.
More informationIschemia of lower extremity icd 10
Ischemia of lower extremity icd 10 This is the 2018 version of the ICD-10- CM diagnosis code I73.89 equina claudication; Intermittent claudication; Ischemia of left lower extremity; Ischemia of. ICD-10-CM
More informationCMS Limitations Guide - Radiology Services
CMS Limitations Guide - Radiology Services Starting October 1, 2015, CMS will update their existing medical necessity limitations on tests and procedures to correspond to ICD-10 codes. This limitations
More informationCMS Limitations Guide - Cardiovascular Services
CMS Limitations Guide - Cardiovascular Services Starting October 1, 2015, CMS will update their existing medical necessity limitations on tests and procedures to correspond to ICD-10 codes. This limitations
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
THEME: EFFECTIVENESS OF INRatio2 PT/INR MONITOR Comment Name and number organisation 1. Consultee 10: Alere Section number Section1 Comment We do not agree that the INRatio2 PT/ INR monitor is only recommended
More informationNorth East Essex Medicines Management Committee
Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES
More informationBreast Reconstruction Following Mastectomy or Lumpectomy
Breast Reconstruction Following Mastectomy or Lumpectomy [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr go to Comunicados a Proveedores, and click Cartas
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cardiovascular Magnetic Resonance (CMR) Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cardiovascular Magnetic Resonance (CMR) Professional Institutional
More informationA Look at Patient Compliance to INR Testing and Therapeutic Range Management of Patients on Warfarin at Agassiz Medical Center.
A Look at Patient Compliance to INR Testing and Therapeutic Range Management of Patients on Warfarin at Agassiz Medical Center Lauren Martens Abstract This study sought to determine the total number of
More informationClinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18
Clinical Policy: (Pradaxa) Reference Number: CP.PMN.49 Effective Date: 05.01.12 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14 THROMBOEMBOLISM PROPHYLAXIS
MEDICAL POLICY SUBJECT: LIMB PNEUMATIC COMPRESSION PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationCY2017 Hospital Outpatient: Vascular Procedure APCs and Complexity Adjustments
CY2017 Hospital Outpatient: Vascular Procedure APCs and Complexity Adjustments Comprehensive Ambulatory Payment Classifications (c-apcs) In CY2015 and in an effort to help pay providers for quality, not
More informationINDIANA HEALTH COVERAGE PROGRAMS
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER CODE TABLES Note: Due to possible changes in Indiana Health Coverage Programs (IHCP) policy or national coding updates, inclusion of a code on the code tables
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationClinical Medical Policy Department Clinical Affairs Division DESCRIPTION
Pneumatic Compression Devices for Lymphedema Treatment [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr go to Comunicados a Proveedores, and click Cartas
More informationYES. Your Guide to Getting WATCHMAN. Is a life without blood thinners possible?
Your Guide to Getting WATCHMAN Is a life without blood thinners possible? YES. WATCHMAN is for people with atrial fibrillation not caused by a heart valve problem who need an alternative to warfarin for
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationCMS Limitations Guide MRA Radiology Services
CMS Limitations Guide MRA Radiology Services Starting July 1, 2008, CMS has placed numerous medical necessity limits on tests and procedures. This reference guide provides you with all of the latest changes.
More informationMEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT
INFUSION SERVICES & EQUIPMENT Effective Date: August 1, 2017 Review Dates: 10/95, 12/99, 12/01, 11/02, 11/03, 11/04, 10/05, 10/06, 10/07, 10/08, 10/09, 4/10, 4/11, 4/12, 4/13, 5/14, 5/15, 2/16, 2/17, 5/17
More informationPolicy #: 291 Latest Review Date: February 2013
Effective for dates of service on or after April 1, 2013, refer to: https://www.bcbsal.org/providers/policies/carecore.cfm Name of Policy: Magnetic Resonance Angiography (MRA) of the Chest (excluding the
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationBILLING BULLETIN. Re: Interventional Cardiology. Bulletin #: 1. Date Issued: November 10, Background
BILLING BULLETIN Re: Interventional Cardiology Bulletin #: 1 Date Issued: November 10, 2016 Background This Billing Bulletin provides billing guidance when submitting claims to Manitoba Health, Seniors
More informationVESSELS: GROSS ANATOMY
ACTIVITY 10: VESSELS AND CIRCULATION OBJECTIVES: 1) How to get ready: Read Chapter 23, McKinley et al., Human Anatomy, 4e. All text references are for this textbook. 2) Observe and sketch histology slide
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/19768 holds various files of this Leiden University dissertation. Author: Langevelde, Kirsten van Title: Are pulmonary embolism and deep-vein thrombosis
More informationHead MRA/MRV studies of the head may be considered medically necessary for the following strongly suspected vascular diseases:
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): January 28, 2014 Effective Date: September 5, 2014 I. POLICY Head MRA/MRV studies of the head may be considered medically
More informationMP.015.MH Compression Stockings and Garments
MedStar Health, Inc. POLICY AND PROCEDURE MANUAL MP.015.MH Compression Stockings and Garments This policy applies to the following lines of business: MedStar Employee (Select) MedStar MA DSNP CSNP MedStar
More informationDr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust
MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital
More informationWhat is the icd 10 code for dvt prophylaxis
What is the icd 10 code for dvt prophylaxis This list presents a sub-set of the Read Code system based on public domain information. It is at present likely to contain some errors and is provided for general.
More information6 semanas de embarazo. Critical pt inr levels. Inicio / Embarazo / 6 semanas de embarazo
Inicio / Embarazo / 6 semanas de embarazo 6 semanas de embarazo Critical pt inr levels INR is the result of the patient PT/mean normal PT, exponentially equalized by the ISI. INR levels above 4.9 are considered
More informationSample page. POWER UP YOUR CODING with Optum360, your trusted coding partner for 32 years. Visit optum360coding.com.
2018 Complete Guide for Interventional Radiology An in-depth guide to interventional radiology coding, billing, and reimbursement for facilities and physicians POWER UP YOUR CODING with Optum360, your
More informationCardiology/Cardiothoracic
Cardiology/Cardiothoracic ICD-9-CM to ICD-10-CM Code Mapper 800-334-5724 www.contexomedia.com 2013 ICD-9-CM 272.0 Pure hypercholesterolemia 272.2 Mixed hyperlipidemia 272.4 Other and hyperlipidemia 278.00
More informationExtracorporeal Membrane Oxygenation (ECMO)
Extracorporeal Membrane Oxygenation (ECMO) Policy Number: Original Effective Date: MM.12.006 05/16/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/01/2014 Section: Other/Miscellaneous
More informationCY2015 Hospital Outpatient: Endovascular Procedure APCs and Complexity Adjustments
CY2015 Hospital Outpatient: Endovascular Procedure APCs Complexity Adjustments Comprehensive Ambulatory Payment Classifications (c-apcs) CMS finalized the implementation of 25 Comprehensive APC to further
More informationORTHOGNATHIC SURGERY
ORTHOGNATHIC SURGERY MEDICAL POLICY Effective Date: February 1, 2017 Review Dates: 1/93, 7/95, 10/97, 4/99, 10/00, 8/01, 12/01, 4/02, 2/03, 1/04, 1/05, 12/05, 12/06, 12/07, 12/08, 12/09, 12/10, 12/11,
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 16 December 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL
More informationContractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC B. LCD ID Number: L34834 Status: A-Approved
LCD for Blood Glucose Monitoring in a Skilled Nursing Facility (SNF) (L34834) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12502 Contractor Type: MAC B LCD ID Number: L34834 Status: A-Approved
More informationWarfarin & You By V. B. Blake
Warfarin & You By V. B. Blake Warfarin is an anticoagulant used to to prevent heart attacks, strokes, and blood clots. Learn about side effects, interactions and indications. Can you tell me what I should
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationDiabetes Management, Equipment and Supplies
Coverage Summary Diabetes Management, Equipment and Supplies Policy Number: D-001 Products: UnitedHealthcare Medicare Advantage Plans Original Approval Date: 11/01/2006 Approved by: UnitedHeatlhcare Medicare
More information